Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, according to the federal clinical trials database. About eight months ago, Asceneuron disclosed a ...
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, according to the federal clinical trials database.
About eight months ago, Asceneuron disclosed a ...
